Keyword: Eli Lilly

The imminent departure leaves Pfenex without a CMO as it gears up to file a new drug application (NDA), although Chen will continue to advise the biotech.

Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.

MD Anderson and Accelerator Life Science Partners unveiled Magnolia Neurosciences, to develop neuroprotective drugs with a $31 million series A.

Karuna will start mid-stage trials of a Lilly drug, shelved due to side effects, as part of a combination therapy for schizophrenia later this year.

Eli Lilly doubles down on its collaboration with the Dana-Farber Cancer Institute, extending the partnership for another three years.

Anima Biotech has signed a deal with Eli Lilly potentially worth more than $1 billion in biobucks as the pair seek to work on the biotech’s translation inhibitors.

Pfizer and Eli Lilly’s NGF inhibitor tanezumab is closer to becoming an alternative to opioid analgesics for pain after a positive phase 3 trial.

The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.

Adlai Noryte grabbed worldwide rights to Novartis' buparlisib, an oral PI3K inhibitor that has run into toxicity issues.

Biogen and Eisai’s phase 2 Alzheimer’s trial has re-emerged, slowing clinical symptom decline and reducing amyloid plaque accumulation in the brain.